BUSINESS

Kalamazoo Manufacturing Site-Joe Biden-Albert Bourla-Pfizer-Getty-Images-1231265811
Pfizer Calls the Shots When It Comes to Government Vaccine Contracts
Pharma giant Pfizer-BioNTech reportedly dictates the governmental vaccine deals it engages in. According to a consumer rights watchdog report, the company has the power to influence governments, supply chains, and consumers. The common theme of...
Evergrande-group-real-estate-crisis-China-credit-rating-downgrade-getty-images-1342296605
Debt-Besieged Evergrande Wins Small Triumph With US$83-Million Bond Payment
With more than $300 billion in outstanding debt, the Chinese real estate giant is by no means out of the woods  Shenzhen-based Chinese real estate company Evergrande narrowly avoided a default on Oct. 21, making...
Evergrande-Group-Debt-crisis-offshore-investors-not-priority-getty-images-1345348075
Offshore Investors in Trouble as Evergrande Favoring Domestic Obligations
With liabilities of more than $300 billion, China’s Evergrande Group is the one of most indebted property developers in the world. Having failed to make payments on some of its debts, Evergrande is making offshore...
new-york-stock-exchange-us-flags
The Silent Influence of the ‘China Model’ on US Economic Policy
Most analyses of the Chinese economy belong to one of two types: those that come from the venture capital industry and those created by think tanks. The venture capitalists are pessimistic about the Chinese economy’s...
cargo-supply chains-Biden-Biden administration-Labour Department-Producer Price Index-inflation-hyperinflation-shortage-Food Prices-Rent-Fuel-Federal Reserve-crisis-Getty-Images-1346437290
COVID-19 Crisis Fans Inflation of Food Prices, Rent, and Fuel
Consumer prices rose 8.6 percent last year induced by skyrocketing energy tariffs that are further hampering supply chains caused by understaffing due to stiff COVID-19 regulations and soaring sick leaves. The US Bureau of Labor...
Moderna-Pfizer-Johnson & Johnson-Janssen-booster-shot-J&J-vaccine-COVID-19-Getty-Images-1232608690
FDA Weighs Endorsing a Johnson & Johnson Booster Shot
On Oct. 13, U.S. drug regulators said a second shot of Johnson & Johnson’s single-shot COVID-19 vaccine could bolster people’s protection against the disease, but regulators did not have enough time to analyze the data...
Southwest Airlines Cancels More Than 1800 Flights; Blames Air Traffic Control Issues, Weather
Since Friday, Southwest Airlines has canceled more than 1800 flights, igniting speculation about a massive walkout of staff after the company announced mandatory vaccination for all employees. Instead, Southwest blamed the cancellations on the weather,...
A contact tracing QR code is seen at the entrance of a restaurant in Sydney on July 13, 2021. Rashays, a 27-location chain based in Sydney, says it will not reopen its doors when the New South Wales government relaxes restrictions on Oct. 1. Instead, Rashays will wait until Dec. 1 when vaccine passports are scheduled to be scrapped entirely. Co-founder Rami Ykmour said his company expects to lose $10 million during the delay, but feels the sacrifice is worth it for their business values.
Australian Restaurant Chain Expects to Lose $10 Million to Postpone Reopening Until ‘It’s a One-tier Society’
A 27-location restaurant chain in Australia’s New South Wales (NSW) state will remain closed after the government relaxes Coronavirus Disease 2019 (COVID-19) measures on Oct. 11, waiting until the so-called “Freedom Day” where the government...
The headquarters of Merck in Darmstadt on November 22, 2019 in Germany. Merck’s antiviral COVID-19 pill, molnupiravir, was developed with $35 million in NIH and NIAID taxpayer funding at Emory University. Now, Merck is selling it back to the government at 35 times the cost of its generic counterpart.
The NIAID and NIH Financed Development of Merck’s COVID Pill, Now They’re Selling to Taxpayers at 3,500% Markup
Merck’s recently announced pill-based antiviral treatment for COVID-19 was researched and developed at a U.S. university using taxpayer funds. Now, the pharmaceutical giant is selling it back to the government at 35 times the cost...